EarDiTech

Millions of individuals (12% of the normal hearing population) suffer from cochlear synaptopathy (CS), also known as hidden hearing loss, which cannot be detected by traditional audiograms. This condition affects speech perception, especially in noisy environments, leading to cognitive decline and a reduced quality of life. Despite its prevalence, there are no effective early diagnosis tools, creating an unmet need and market opportunity for innovative diagnostics and treatment solutions in hearing health.

EarDiTech offers a patented diagnostic tool, the CochSyn Test, which utilises EEG-based measurements to detect biomarkers for CS, along with the CoNNear Algorithm, a personalised AI-based speech processing solution. These innovations are protected by multiple patents and validated through scientific studies. The technology not only provides early diagnosis but also enhances the audiology and hearing aid fitting processes. EarDiTech’s diagnostic test and algorithm target both the hearing aid and medical device markets, addressing a total market opportunity of over EUR 390 million.